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A B S T R A C T
NADPH oxidase 4 (NOX4) is a redox active, membrane-associated protein that contributes to genomic instability,
redox signaling, and radiation sensitivity in human cancers based on its capacity to generate H2O2 constitutively.
Most studies of NOX4 in malignancy have focused on the evaluation of a small number of tumor cell lines and
not on human tumor specimens themselves; furthermore, these studies have often employed immunological
tools that have not been well characterized. To determine the prevalence of NOX4 expression across a broad
range of solid tumors, we developed a novel monoclonal antibody that recognizes a speciﬁc extracellular region
of the human NOX4 protein, and that does not cross-react with any of the other six members of the NOX gene
family. Evaluation of 20 sets of epithelial tumors revealed, for the ﬁrst time, high levels of NOX4 expression in
carcinomas of the head and neck (15/19 patients), esophagus (12/18 patients), bladder (10/19 patients), ovary
(6/17 patients), and prostate (7/19 patients), as well as malignant melanoma (7/15 patients) when these tumors
were compared to histologically-uninvolved specimens from the same organs. Detection of NOX4 protein
upregulation by low levels of TGF-β1 demonstrated the sensitivity of this new probe; and immunoﬂuorescence
experiments found that high levels of endogenous NOX4 expression in ovarian cancer cells were only
demonstrable associated with perinuclear membranes. These studies suggest that NOX4 expression is
upregulated, compared to normal tissues, in a well-deﬁned, and speciﬁc group of human carcinomas, and that
its expression is localized on intracellular membranes in a fashion that could modulate oxidative DNA damage.
1. Introduction
Cellular redox balance relies on a dynamic interplay between
endogenous [mitochondria, cytochrome P-450, nitric oxide synthase
(NOS) and NADPH oxidase (NOX) enzymes] and exogenous (environ-
mental agents, pharmaceuticals, and industrial chemicals) production
of reactive oxygen species (ROS) and a broad array of intrinsic cellular
antioxidant pathways [1–3]. Understanding the mechanisms by which
ROS imbalance results in epithelial dysfunction and promotes tumor
growth and progression could focus development of new redox-based
strategies for therapeutic intervention. The NOX enzymatic family
members (NOX1-5, DUOX1-2), through isoform speciﬁc superoxide or
hydrogen peroxide production, have been associated with tissue
remodeling, resistance to apoptosis, tumor cell proliferation and
metastasis, and enhanced angiogenesis. Tumor promotion by NOX
isoforms occurs, in part, by inﬂammation- and hypoxia-mediated
upregulation of oxidative DNA damage and tissue injury [4–8].
The relationship between NOX-related oxidant production and
cancer is both NOX-isoform and tumor context speciﬁc. For example,
aberrant hypermethylation of the DUOX1 and DUOX2 promoters results
in downregulation of both DUOXs in lung cancer [9]. DUOX1 has also
been implicated in the process of wound repair [10]; recently, loss of
DUOX1 expression has been linked to a loss of E-cadherin and
subsequent enhanced epithelial-mesenchymal transition (EMT) [11].
DUOX2 expression, unlike that of the DUOX1 homolog, is associated
with progression of pancreatic cancer; the pro-inﬂammatory cytokine
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IFN-γ triggers Stat1-mediated DUOX2/DUOXA2 up-regulation in pan-
creatic cancer cell lines, contributing to increased intra- and extra-
cellular ROS production [12]. Increased DUOX2-derived ROS produc-
tion is also associated with increased VEGF and HIF-1α expression in
pancreatic cancer cell lines; evaluation of malignant versus matched
non-malignant pancreatic tissues also demonstrated DUOX2-related up-
regulation of VEGF expression [13]. While DUOX2 has also been
implicated in other gastrointestinal malignancies, NOX1 is primarily
involved in the proliferative potential of colonic malignancies. Proﬁles
of pre-cancerous large bowel adenomas, as well as moderately- and
well-diﬀerentiated adenocarcinomas of the colon, have demonstrated
substantial NOX1 overexpression [7,14]. It has been proposed that
increased ROS levels derived from elevated NOX1 expression may
stimulate tumor initiation through activation of NF-κB signaling
[15,16].
Studies of NOX4 in cancer have focused on malignancies of the
brain, breast, bladder, liver, kidney, and ovary, as well as melanoma
[17–23], primarily in human tumor cell lines. NOX4 has been asso-
ciated with the formation of invadopodia [24], cell proliferation [25],
diﬀerentiation [26], and EMT [20]. A membrane-bound, hydrogen
peroxide-producing enzyme, NOX4 requires a single interaction partner
for its activity, p22phox [27–31]. ROS production by this isoform is
constitutive, in contrast to the other six NOX family members, whose
activities are regulated by protein partner translocation or calcium
stimulation [30,32,33]. Constitutive activity is unexpected in view of
the harmful eﬀects of excessive ROS production; but, to date, enzyme
abundance, stimulated by TGF-β1 [25,34–37], hypoxia and hyperoxia
[38–41], or vascular injury [42,43], appears to be the only known
mechanism controlling NOX4 ROS production. Furthermore, NOX4 is
widely distributed; its expression has been demonstrated in osteoclasts
[44], ﬁbroblasts [34,37], and adipocytes [45], as well as endothelial
[46] and mesangial cells [47]. Developing a uniﬁed understanding of
the cellular localization and physiological function of NOX4 remains an
area of active investigation.
Conﬂicting reports place NOX4 on the membranes of perinuclear
vesicles [30], in the nucleus [48–50], mitochondria [51], or endoplas-
mic reticulum (ER) [29,30,33,52], in focal adhesions [50] or on the
plasma membrane [53,54]. These reported diﬀerences may be the
result of cell type, overexpression system design (i.e. aﬃnity tag
placement), and/or speciﬁcity of the antibody used for study. Approxi-
mately 40 commercial NOX4 antibodies are currently available; most
are polyclonal and rabbit-derived. Academic antibody sources have
generally proven to be the only reliable NOX4 antibodies to date, but
most lack monoclonal character and/or were raised against an intra-
cellular antigen [55]. The lack of freely available, well-characterized,
sensitive antibodies for investigative eﬀorts has limited progress
evaluating endogenous expression, localization, and tissue distribution.
Here, we present comprehensive characterization of a novel NOX4
monoclonal antibody raised to an extracellular domain, and demon-
strate its utility for investigating the role of NOX4 in tumor biology.
Evaluation of antibody binding to portions of the E-loop region deﬁned
a recognition motif of 21 amino acids; sequence divergence with mouse
Nox4 suggested distinct detection of the human NOX4 protein, which
was experimentally veriﬁed for our monoclonal antibody. Through
application of this new tool, we found that TGF-β1-stimulated ﬁbro-
blasts demonstrated sensitivity to a lower, biologically relevant level of
NOX4 protein. Of greatest pertinence, extensive screening of a panel of
20 malignancies and associated normal tissues investigated the relative
expression of NOX4 in human epithelial tumors. Deﬁned diﬀerential
NOX4 expression favoring increased protein in tumor was found for
carcinomas of the bladder, esophagus, head and neck, prostate, and
ovary as well as malignant melanoma. Importantly, NOX4 was ex-
pressed in almost all of the melanomas studied (14/15, 93%) and none
of the normal skin samples (n=8); overexpression of NOX4 was
detected in 15/17 (88%) of ovarian carcinomas. Finally, subsequent
investigations in ovarian cancer cell lines established that NOX4 protein
is localized to perinuclear membranes.
2. Materials and methods
2.1. Materials, facilities, and general instrumentation
Recombinant human TGF-β1 (catalog no. 7754-BH-005) was pur-
chased from R &D Systems. Anti-p22ph°x antibody (catalog no. FL-195),
NOX2 antibody 54.1 (catalog no. sc-130543) and Rabbit IgG (catalog
no. sc-2027) were purchased from Santa Cruz Biotechnology. Anti-β-
actin (catalog no. 3700), anti-HA-tag (catalog no. 2367), anti-Myc-tag
(catalog no. 2276), anti-GAPDH (catalog no. 2118), anti-Vinculin
(catalog no. 13901), anti-Na/K-ATPase (catalog no. 3010) and the
SMAD 2/3 antibody kit (catalog no. 12747) were purchased from Cell
Signaling Technology. The NOX1 mouse monoclonal antibody (NOX1-
Hyb-Clone-22) used for Western analysis was raised against a truncated
recombinant protein representing 341 amino acids (224–564 amino
acid sequence) at the carboxyl-terminus of the human NOX1 protein
[56]. DUOX protein immunoblot detection was performed using a
mouse monoclonal antibody S-40 that was raised against the human
DUOX2 131–540 amino acid fragment [57]. DNA sequencing was
performed by Genewiz (Frederick, MD). The entire gene insert was
completely sequenced for each plasmid construct. All experiments were
performed at room temperature unless otherwise stated. Results are
expressed as the mean± S.D. from at least triplicate experiments.
Statistical diﬀerences between mean values of control and treated
samples were assessed using Student's t-test; p< 0.05 was considered
statistically signiﬁcant. Signiﬁcance levels were designated as *,
p<0.05 and ***, p<0.001 throughout.
2.2. Generation of the rabbit monoclonal NOX4 antibody
Immunization of rabbits and NOX4 monoclonal antibody produc-
tion were carried out by Abcam, (Burlingame, CA) using the following
procedure. Overexpressing NOX4 HEK293 stable cells were harvested
from culture plates (500 million cells) and ethanol ﬁxed in 100 million
cell aliquots, subsequently provided to Abcam. A second 74 amino acid
peptide immunogen was synthesized (NOX4 amino acids 209–282)
representing the extracellular E-loop region of the human NOX4
protein. After six alternating rounds of immunization with ﬁxed cells
or peptide immunogen, the harvested serum titer reached signiﬁcance
as tested by ELISA against the immunogenic peptide. Subsequent to
hybridoma fusion, supernatants were collected and multi-clones were
evaluated for antigenic response. Six multiclones were selected and
subcloned; supernatants harvested from 3 subclones (developed from
each multiclone) were received and evaluated. One subclone from each
multi-clone was chosen for antibody puriﬁcation. After extensive
evaluation, subclone 47-6 was chosen for sequencing and exclusive
use in NOX4 studies.
2.3. Sequencing of the variable region of the NOX4 rabbit mAb coding
region (GenScript)
Total RNA was extracted from the NOX4 hybridoma clone 47-6
using TRIzol reagent and analyzed by gel electrophoresis. RT-PCR was
performed using isotype-speciﬁc antisense primers or universal primers
according to the technical manual of the PrimeScript First Strand cDNA
Synthesis Kit (catalog no. 6110 A, Clontech). Ampliﬁed antibody
fragments were separately cloned into a standard cloning vector using
standard molecular cloning procedures. Colony PCR screening was
performed to identify clones with inserts of correct sizes. Five single
colonies with inserts of correct sizes were sequenced for each antibody
fragment (VH and VL).
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2.4. Cell culture and transfection
HEK293 (CRL-1573) embryonic kidney and CCD-19Lu (CCL-210)
lung ﬁbroblast cells were obtained from ATCC (Manassas, VA) and
cultured using ATCC recommended medium supplemented with 10%
FBS. COV362 ovarian cancer cells were obtained from Sigma Aldrich
(catalog no. 07071910) and cultured using DMEM medium supplemen-
ted with 10% FBS. SKOV3 ovarian cancer cells and RPMI 8226
myeloma cells were obtained from the Developmental Therapeutics
Program of the National Cancer Institute (Frederick National
Laboratory, Frederick, MD) and cultured in McCoy's 5 A medium
supplemented with 10% FBS and RPMI-1640 medium supplemented
with 10% FBS, respectively. Each cell line identity was conﬁrmed by
the Genetic Resources Core Facility of Johns Hopkins University
(Baltimore, MD, USA). All cell lines were tested to ensure the absence
of Mycoplasma contamination and maintained at 37 °C in a humidiﬁed
atmosphere of 5% CO2 and 95% air. cDNA transfection into cells was
carried out using the Amaxa Nucleofector™ system from Lonza,
according to the manufacturer's protocol.
For transient transfections of plasmid DNA, [pCMV-MycDDK-
HsNOX4 (catalog no. RC208007, Origene) or pCMV-MmNOX4-
3xHA6His (EX-Mm06833-M08, GeneCopoeia)] 4 μg cDNA was trans-
fected into HEK293 using the Lonza system (Kit V, Program Q-001).
Cells were incubated for 48 h at 37 °C before harvest and evaluation. To
generate a stable, clonal cell line overexpressing NOX4, HEK293 cells
were transfected with a pCMV-MycDDK-HsNOX4 plasmid or pCMV-
Entry vector again using the Lonza system (Kit V, Program Q-001).
Resistant clones were selected with 750 µg/mL G418 (catalog no. 5005;
Teknova, Hollister, CA), and single clones were then maintained under
G418 selection. For antibody selectivity studies, both NOX1- and NOX5-
overexpressing cell lines were developed in-house. Brieﬂy, stable
NOX1/NOXA1/NOXO1 cells were initiated by transfection of pCMV-
NOX1(3 μg) plasmid in HEK293 cells using the Lonza system (Kit V,
Program Q-001), followed by selection with G418. After stable clones
were achieved and validated by qPCR, a single clone was selected for
transfection with pCMV-NOXA1/NOXO1 (3 μg) and single clones were
selected with puromycin. The ﬁnal, active NOX1 overexpression clonal
cell line was maintained with 500 μg/mL G418 and 500 ng/mL
puromycin (catalog no. P9620, Sigma). To generate human cells that
stably over-express NOX5, KARPAS 299 lymphoma cells (Sigma) were
transfected with pcDNA3-NOX5β plasmid (a kind gift from Dr. David J.
R. Fulton, Medical College of Georgia) using lipofectamine2000
(Invitrogen, Carlsbad, CA, USA) per the manufacturer's protocol.
Resistant clones were selected with 800 μg/mL G418, and then single
clones were selected and maintained in RPMI-1640 media supplemen-
ted with 2 mM glutamine and 10% FBS, under 500 µg/mL G418
selection. KARPAS 299-NOX5 overexpressing clones were validated
by Western analysis using antibodies speciﬁc for NOX5 protein and the
HA tag [58]. The stable HEK293 cell line expressing both the human
DUOX2 and DUOXA2 enzymes was kindly provided by Dr. William M.
Nauseef (University of Iowa, Iowa City, IA, USA) and maintained in
DMEM:F12 medium supplemented with 10% FBS, 800 μg/mL G418 and
250 μg/mL Zeocin (catalog no. 46–0509; Invitrogen).
2.5. RNA isolation and quantitative real-time PCR analysis
For quantitative real-time PCR (qPCR), total RNA was extracted
from cells using the RNeasy Mini Kit (catalog no. 74104; Qiagen)
according to the manufacturer's instructions. Following isolation, RNA
concentrations and purity were measured on the Nanodrop ND-1000
apparatus (Nanodrop Technologies, Wilmington, DE). Two μg of total
RNA was used for cDNA synthesis, and combined with SuperScript II
reverse transcriptase (catalog no. 100004925; Invitrogen) and random
primers (catalog no. 48190-011; Invitrogen) in a 20 μL reaction system.
Cycling conditions were as follows: 25 °C for 10 min, 42 °C for 50 min,
70 °C for 15 min. After reaction, the products were diluted with H2O to
100 μL and RT-PCR was performed on 384-well plates in a 20 μL
reaction system containing 2 μL of diluted cDNA and 1 μL of appro-
priate primer. Human NOX4 primer (catalog no. Hs00418356_m1),
mouse NOX4 primer (catalog no. Mm00479246_m1), human CYBA
(p22phox, catalog no. Hs00164370_m1), human β-actin (catalog no.
Hs99999903_m1), and TaqMan Universal PCR mix (catalog no.
4364340) were purchased from Applied Biosystems for the reaction.
PCR ampliﬁcation was performed on an ABI 7900HT sequence detec-
tion system (Applied Biosystems, Foster City, CA). Relative gene
expression was calculated as the ratio of the target gene to the internal
reference gene (β-actin) multiplied by 106 based on the Ct values.
2.6. Plasmid constructs for antibody recognition site identiﬁcation
Mutations encoding stop codons in pCMV-MycDDK-HsNOX4 were
introduced by QuikChange site-directed mutagenesis (Clontech), ac-
cording to the manufacturer's instructions, to create four truncated
NOX4 constructs. Primer sequences are listed in Supplementary
Table 1; (pJLM123-126). The entire open reading frame was sequenced
for each new plasmid.
2.7. Western analysis
For preparation of whole-cell extracts, cell pellets from HEK293,
NOX4 HEK293 stable clones, and CCL-210 cells were lysed with 1X
RIPA lysis buﬀer (catalog no. 20–188; Millipore, Temecula, CA), with
the addition of a 1X protease inhibitor cocktail (catalog no.
11–836–153001; Roche) and 1 mM PMSF. The protein concentrations
of resulting lysates were measured by using the BCA Protein Assay Kit
(Pierce). Cell extracts were mixed with an equal volume of 2X SDS
protein gel loading buﬀer (catalog no. 351-082-661; Quality Biological)
and loaded, without boiling, onto a 4–20% Tris glycine gel (catalog no.
EC6028; Invitrogen). Proteins were separated and dry transferred to
nitro-cellulose membranes using the iBlot 2 gel transfer system (Thermo
Fisher Scientiﬁc). The membranes were blocked in 1X TBST buﬀer with
5% non-fat milk or 1X TBS buﬀer with 3% non-fat milk for 1 h at room
temperature and then incubated with primary antibody overnight in
TBST (milk) buﬀer. Membranes were washed three times in 1X TBS
buﬀer and incubated with HRP-conjugated secondary antibody for
1–2 h at room temperature with shaking. The antigen-antibody com-
plex was visualized with SuperSignal West Pico Luminol/Enhancer
Solution (catalog no. 1856136, Thermo Fisher Scientiﬁc) or ECL-Plus
reagent (catalog no. 32132; Pierce).
2.8. Membrane preparation of COV362 and OVCAR3 cell lines
Approximately 200 million cells were harvested for both COV362
and OVCAR3 cell lines, washed with PBS, and stored as frozen pellets at
−80 °C until ready for preparation. On the day of preparation, cell
pellets were thawed on ice, then resuspended in 1.25 mL sonication
buﬀer (11% sucrose, 120 mM NaCl, 1 mM EGTA in PBS, pH 7.4 +
1 mM PMSF added just prior to sonication). The cell suspensions were
sonicated (2X) for lysis and the resulting lysates were centrifuged to
collect unbroken cells and nuclei (200g, 10 min, 4 °C). The cell pellets
were resuspended in 500 μL sonication buﬀer after which sonication
(1X) and centrifugation were repeated. Both lysates collected from
above the cell pellets were combined for application to a sucrose
gradient. A discontinuous sucrose gradient was prepared at 4 °C,
consisting of 17% and 40% (w/v) sucrose layers. The lysates were
carefully added to the top of the gradient and centrifuged at 40,000 rpm
(Beckman XL-90 ultracentrifuge) for 30 min. Fractions were isolated
from the top of the gradient to the 17%/40% sucrose layer interface in
1 mL increments; cytosolic protein was collected as the second fraction
within the 17% layer, and membrane protein was isolated as fraction 8
at the sucrose layer interface.
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2.9. siRNA-mediated NOX4 gene silencing
COV362 cells were transfected with 5 nM non-targeting pool siRNA
(catalog no. D-001810-10-05), NOX4 SMARTpool siRNA (catalog no. L-
010194-00), or NOX4 #07 individual siRNA (catalog no. J-010194-07)
from Dharmacon, utilizing RNAiMAX Lipofectamine™ transfection
reagent (catalog no. 13778; Invitrogen). Transfected cells were har-
vested 96 h post-treatment, and silencing eﬃciency was evaluated at
both the RNA (qPCR) and protein level (immunoblot).
2.10. Extracellular H2O2 measurement using Amplex Red®
The Amplex Red® Hydrogen Peroxide/Peroxidase Assay Kit (catalog
no. A22188; Invitrogen) was used to detect extracellular H2O2 release.
Assay kit buﬀer was replaced with KRPG buﬀer to facilitate whole cell
assays of signiﬁcant time duration (up to 2 h). The ﬂuorescence of the
oxidized 10-acetyl-3,7-dihydroxyphenoxazine was measured at an
excitation wavelength of 530 nm and an emission wavelength of
590 nm, using a SpectraMax Multiplate reader (Molecular Devices,
Sunnyvale, CA); 20,000 cells per well were evaluated for each assay
condition, in triplicate·H2O2 was quantiﬁed by an H2O2 standard curve
over a concentration range from 0 to 2 μM.
2.11. Superoxide anion assay
Superoxide production was measured using chemiluminescent
probe L-012. As a positive control, a single site mutation (H222Q),
reported to result in superoxide production, was generated in pCMV-
MycDDK-HsNOX4 using Quikchange mutagenesis. Brieﬂy, HBTS buﬀer
was prepared prior to cell trypsinization. HEK293 parental, H222Q
mutant NOX4 and wild-type NOX4 stable cell lines were counted after
detachment and washed with assay buﬀer once; 750,000 cells per well
were resuspended in HBTS for assay plate addition. A 20 μM reaction
solution of L-012 in HBTS was prepared (with or without antibody or
SOD); 100 μL reaction solution was combined with 100 μL resuspended
cells per well and the resulting assay was monitored by chemilumines-
cence at 37 °C for 30 min.
2.12. Immunoﬂuorescence detection by confocal microscopy
Parental and stable NOX4 overexpressing HEK293 cells (Clone WT1
and WT2) were visualized using Permanox 4-well chamber slides
(catalog no. 177437; Thermo Fisher Scientiﬁc). Prior to cell addition,
chamber slides were treated with a sterile solution of Poly-D-lysine
(catalog no. P7405; Sigma Aldrich) for 5 min. Slides were allowed to
dry for at least 2 h after solution removal prior to seeding. HEK293
parental and NOX4 overexpressing cells (5.0×103) were ﬁxed 72 h post
seeding, with 4% (w/v) paraformaldehyde for 10 min at room tem-
perature. After two washes with PBS, cells left non-permeabilized were
blocked with 4% BSA in PBS at room temperature for one hour. For
permeabilization, cells were treated with 0.1% Triton X-100 (v/v) for
5 min prior to blocking. After one remaining wash, the cells were
incubated overnight at 4 °C with the rabbit monoclonal NOX4 (47-6)
antibody at 2 μg/mL in PBS containing 0.5% (w/v) BSA. As a negative
control, select cells were incubated with rabbit IgG. Following 3 washes
with PBS, a secondary Alexa Fluor 488 goat anti-rabbit antibody
[1:1000 in PBS containing 0.5% (w/v) BSA], catalog no. A-11034
was added. After a 1 h incubation, cells were washed, and the cell
nuclei were stained with propidium iodide (PI, 0.5 µg/mL). Samples
were then mounted in Vectashield solution, sealed, and stored at room
temperature in the dark.
COV362 and SKOV3 ovarian cancer cells were visualized using glass
4-well chamber slides (catalog no. 154526; Thermo Fisher Scientiﬁc).
The slides were pretreated with Poly-D-lysine, as previously described
for Permanox slides, prior to cell addition. COV362 (2.5×103) and
SKOV3 (2.0×103) cells were attached and ﬁxed 72 h post seeding.
Fixation and antibody staining proceeded as previously described,
modiﬁed after secondary antibody treatment with rhodamine phalloi-
din staining (catalog no. R415; Molecular Probes), 25 μL/1 mL PBS for
10 min at room temperature, followed by mounting with Vectashield
containing DAPI.
Confocal microscopy was carried out at the confocal microscopy
core facility (NCI) using a Zeiss LSM 710 NLO confocal scanning
microscope equipped with an Argon/2 laser (458, 488, and 514 nm),
a diode laser (561 nm), and a HeNe laser (633 nm).
2.13. Immunodetection by ﬂow cytometry
Log phase parental, vector control, and stable NOX4-overexpressing
(Clone WT1 and WT2) HEK293 cells were trypsinized, washed in cold
PBS, pelleted, and resuspended in a cold PBS/FBS solution (PBS
containing 5% fetal bovine serum). Live cells were not ﬁxed prior to
labeling to promote extracellular epitope recognition. Cells to be
permeablized were centrifuged for 5 min at 2000 rpm and ﬁxed with
cold 2% (v/v) paraformaldehyde for 30 min on ice. Following centri-
fugation, the cell pellets were resuspended in room temperature Tween
20 solution (0.15% in PBS) for 15 min in a 37 °C water bath. After
centrifugation, cells (106) were either unlabeled and resuspended in
PBS or labeled with irrelevant rabbit IgG antibody (4 µg) or NOX4-
speciﬁc rabbit monoclonal antibody (47-6, 4 µg) in human AB serum
(heat-inactivated) for 30 min at 4 °C. The labeled cells were then
washed twice with Tween 20 solution (0.15% in PBS) followed by
incubation with secondary Alexa Fluor 488 goat anti-rabbit antibody
[diluted 1:1000 in human AB serum (heat-inactivated)] for 20 min on
ice in the dark. Cells were then centrifuged, washed and resuspended in
PBS. Fluorescence intensity of the cells was measured on a FACScalibur
(Becton Dickinson Biosciences, San Jose, CA) cytometer, acquired using
the data ﬁle acquisition program CellQuest (Becton Dickinson
Biosciences, San Jose, CA) and analyzed using the FlowJo software.
2.14. Immunohistochemistry and tissue microarray
Pellets of SKOV3, COV362, HEK293 vector control, and overexpres-
sing NOX4 (WT1) cells were ﬁxed in 10% buﬀered neutral formalin and
used as controls to optimize conditions for NOX4 immunohistochem-
istry (IHC). Optimal conditions were achieved for the NOX4 mAb (47-6)
at a dilution of 1:750 after heat-induced epitope retrieval in citrate
buﬀer (BioGenex) in a decloaking chamber (Biocare). Primary antibody
incubation occurred overnight at 4 °C, followed by biotinylated sec-
ondary goat anti-rabbit IgG (Vector Laboratories), Vectastain ABC Elite
(Vector Labs) and DAB chromagen. All samples were processed in
parallel with a no-primary-antibody control to evaluate possible
artifactual nonspeciﬁc staining from the secondary antibody. Isotype
control staining was prepared with normal rabbit IgG (Cell Signaling
Technology) at a comparable concentration to the primary antibody.
Following established conditions from the control samples, IHC was
performed on a BioMax multiple organ tissue microarray (TMA)
MC6163. The TMA was deparaﬃnized in alcohol and rehydrated with
graded alcohol prior to antigen retrieval. After immunostaining with
the optimized protocol, slide(s) were bleached with hydrogen peroxide/
potassium hydroxide for 60 min at 37 °C followed by a 20 s acetic acid
rinse to eliminate melanin pigment. Post bleaching, slide(s) were
counterstained with hematoxylin, dehydrated, and cover slipped.
Each slide was digitally imaged using an Aperio ScanScope®. The
veriﬁcation of staining performance was conﬁrmed on a series of cancer
tissue samples. In addition, a series of normal, nontumor tissues were
evaluated to establish immunoreactivity and assay speciﬁcity. Positive
controls that were expected to demonstrate diﬀerent levels of NOX4
included formalin-ﬁxed paraﬃn embedded human liver. Evaluation of
staining on sections exposed to the primary and secondary antibodies
was compared to negative control sections that were not exposed to the
primary antibody. Tissues were scored as positively stained only if they
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exhibited a staining pattern with the primary antibody that was
signiﬁcantly diﬀerent than that found by omitting the primary anti-
body. Those that did not demonstrate a signiﬁcant diﬀerence between
staining with and without the primary antibody were graded as 0+ (no
stain), and 0% stained. Tissues that demonstrated a signiﬁcant diﬀer-
ence between the two conditions were graded as described below. The
assay was interpreted with a scoring system of 0+, 1+, 2+ and 3+,
for staining intensity corresponding to negative, weak, moderate, and
strong NOX4 staining. The percentage of stained tumor/lesion cells
(distribution) was estimated for each case, where 0% to< 10% were
considered negative.
3. Results
3.1. Monoclonal antibody development targeting the extracellular NOX4 E-
loop region
Generation of a monoclonal antibody to the extracellular domain of
NOX4 with suﬃcient sensitivity and speciﬁcity to monitor changes in
enzyme expression by Western blot and TMA for levels of cancer
expression has proven diﬃcult. Many commercial antibodies have
failed in studies attempting to conclusively establish NOX4 localization
and validate the knockdown of NOX4 expression [59,60]. Our approach
toward development of an eﬀective antibody focused on an extracel-
lular region of the NOX4 enzyme termed the E-loop (Fig. 1). Single site
mutation studies within this domain suggest that its disulﬁde-supported
secondary structure or metal binding capability may facilitate super-
oxide to hydrogen peroxide conversion [61]. Targeting this region
could therefore aﬀord some control over ROS generation for therapeu-
tic purposes. A peptide comprised of the amino acids predicted to be
found in this exposed cellular region (amino acids 209–282) was
synthesized. A second immunogen was prepared to permit alternating
rounds of immunization using ﬁxed aliquots of stable NOX4-over-
expressing HEK293 cell membranes. While the NOX4 amino acid
sequence does not display ER retention or endosomal translocation
signals [62], previous studies have reported a lack of NOX4 enzyme at
the plasma membrane surface in overexpression systems established in
HEK293, COS-7, or HeLa parental cell lines [29,30,33,62]. Recently,
plasma membrane association was reported in H661 and COS-7 cells
[53,63]; lack of recognition in earlier studies may be the result of the
detection system utilized or disruption of traﬃcking due to construct
design. Plasma membrane puriﬁcation was performed, and surface
localization conﬁrmed in our overexpressing cells employed as a
secondary antigen (data not shown). Six alternating injections were
performed on 2 rabbit hosts, resulting in 30 ELISA-positive multiclones.
Of these, 6 hybridoma multiclones were selected by Western analysis
for subcloning (Supplementary Fig. 1). One subclone from each multi-
clone (after initial Western blot analysis) was puriﬁed by peptide
aﬃnity column for activity studies; ﬁnally, subclone 47-6 was chosen
for sequencing (Supplementary Fig. 2) and subsequent use in this study.
3.2. Determination of NOX4 antibody (47-6) speciﬁcity by Western
analysis
The NOX4 protein has been identiﬁed in a remarkable number of
cell lines, tissues, and animal model systems, unfortunately, often
without routine RNA validation. Many systems which may contain
the NOX4 protein also exhibit expression of other NADPH oxidases.
Sequence identity is shared between NOX4 and its NOX family
members as follows: NOX1 (36%), NOX2 (39%), NOX3 (36%), and
NOX5 (27%). Interestingly, the NOX4 E-loop is signiﬁcantly longer than
those found in other NOXs (Fig. 1A); this diﬀerence in length has been
conjectured to contribute to ROS species conversion [61,64]. To
ascertain whether our NOX4 antibody is capable of distinguishing
between known NOX isoforms, speciﬁc, high expression systems for
each oxidase were established and compared at the protein level
(Fig. 1B). The NOX4 monoclonal antibody detected an intense band
at ~65 kDa from total protein isolated from stable NOX4 overexpres-
sing cells, consistent with the calculated molecular weight. No cross
reactivity with any other NOX protein was observed, nor were any
signiﬁcant non-speciﬁc bands detected. A low intensity higher mole-
cular weight band (~80 kDa) was also observed for NOX4, and is
consistent with previous observations in HeLa, HUVEC, and vascular
smooth muscle cells [28,50,65]. This higher molecular mass species has
been proposed to be the result of glycosylation or to be due to tight
association of a complexing protein. Staggered start codons at the
beginning of the NOX4 gene also provide the possibility of a shift in the
ORF; signal sequence cleavage from the protein upon translocation
represents another possible explanation.
To expand these initial results, we sought to deﬁne the region of
recognition by our antibody. Plasmid constructs were created through
insertion of stop codons within the ORF of an N-terminal aﬃnity tagged
NOX4 gene to divide the extracellular E-loop region into gradually
excluding segments of amino acids (Supplementary Fig. 3A). Transfec-
tion into HEK293 cells resulted in protein expression of each construct,
as determined by Western analysis with Myc-tag antibody. Evaluation
with the NOX4 antibody demonstrated that recognition of the longest
truncated construct (Stop 4) was signiﬁcantly more intense than the full
length NOX4 protein (Supplementary Fig. 3B). This is most likely due to
greater exposure of the protein recognition region, aﬀording better
access for the NOX4 antibody to bind. Further truncation completely
abolished the ability of the antibody to recognize the NOX4 protein.
Therefore, the amino acids recognized by antibody 47-6 encompass
those found between the sites where stop codons 3 and 4 were placed
(Fig. 1C, Supplementary Fig. 3C).
With a speciﬁc recognition epitope established, further sequence-
based analysis was undertaken for antibody characterization to deter-
mine if mAb 47-6 may exhibit species speciﬁc interactions, or may be
broadly applicable to NOX4 identiﬁcation in many eukaryotes.
Taxonomic studies have established that the NOX4 enzyme and the
NOX1-3 subfamilies originated from a common branch, with expression
across many species, including but not limited to mouse, rat, chicken,
cow, and ﬁsh [64,66,67]. Mouse and rat NOX4 isoforms share 98%
sequence identity; sequence alignment of human, mouse, and rat NOX4
isoforms demonstrated a signiﬁcant region of dissimilarity coinciding
with the region of 47-6 recognition (Supplementary Fig. 4A). To
interrogate whether this sequence divergence may be suﬃcient to
prevent cross-reactivity, Western analysis was carried out using samples
expressing human (MycDDK-HsNOX4) and mouse (MmNOX4-3HA6-
His) NOX4. As observed in Supplementary Fig. 4B, the NOX4 mono-
clonal antibody 47-6 only identiﬁes the human NOX4 protein. Im-
portantly, unlike other antibodies from academic labs developed with
C-terminal NOX4 antigens, 47-6 mAb recognition is unperturbed by C-
terminal aﬃnity tagged constructs (MmNOX4-3HA6His, Supplemental
Fig. 5). While it is unfortunate that the 47-6 antibody is incapable of
NOX4 detection in rodent model studies and knockout systems,
xenograft studies utilizing implanted human tumors in animals may
be more eﬀectively monitored with this tool, due to its inability to
detect contaminating NOX4 from the carrier system.
3.3. NOX4 monoclonal antibody eﬃcacy in confocal and ﬂow cytometry
studies
To further establish utility, the immunoreactivity of the NOX4
antibody was initially characterized with an overexpression system.
Two stable HEK293 NOX4 clones, both veriﬁed to express the NOX4
protein, stabilize p22phox, and produce H2O2, were selected for confocal
microscopy (Supplementary Fig. 6). Both membrane-permeable and
non-permeable cells were evaluated, because NOX4 is expressed at the
plasma surface aﬀording extracellular exposure of the E-loop region.
After staining with a protocol utilizing 2 μg/mL 47-6, parental and
vector stable clones displayed no signiﬁcant background signal, nor did
J.L. Meitzler et al. Redox Biology 13 (2017) 182–195
186
(caption on next page)
J.L. Meitzler et al. Redox Biology 13 (2017) 182–195
187
cells incubated with equimolar rabbit IgG (Fig. 1D). Both overexpres-
sion clones displayed intense staining, with or without Triton-X
permeabilization, consistent with an extracellular antigen derived
antibody recognizing an exposed membrane protein. These results
suggested that the 47-6 antibody is sensitive enough to utilize in
confocal studies to verify localization, and should be further challenged
with an endogenous system.
We sought to assess the applicability of our NOX4 mAb for labeling
of native antigen in HEK293 NOX4 overexpressing stable cells by ﬂow
cytometry (Supplementary Fig. 7). Both NOX4 overexpressing clones
demonstrate considerable NOX4 mAb bound to the permeabilized
overexpressing cells compared to vector control and parental cells.
Increased ﬂuorescence was also noted with intact live overexpressing
NOX4 cells; this result conﬁrms the extracellular antigen design utilized
for antibody development, and further supports localization of NOX4 at
the plasma membrane surface of the HEK293 NOX4 stable overexpres-
sion cell lines.
3.4. Evaluation of activity perturbation by the NOX4 mAb
Sequence modiﬁcations, diﬀerences in transmembrane spanning
regions, as well as extensions at the amino termini all may be critical for
regulatory and functional diﬀerences between individual NADPH
oxidase family members. Regarding NOX4, chimeric proteins developed
by mixing portions of the phagocytic NOX2 and NOX4 enzymes
revealed ROS production by NOX4 is dependent on the B loop region,
perhaps through interaction with the FAD/NADPH binding domain,
and further undeﬁned structural elements in the transmembrane or
extracellular regions [54]. Subsequent ﬂuorescence polarization studies
deﬁned an activity-dependent B-loop interaction with the FAD domain
of NOX4, proposed to maintain a discreet distance between the FAD
region and the membrane helix bound heme moiety(s), aﬀording facile
electron transfer [68]. Further targeted investigation has also deﬁned
the E-loop region of NOX4 as essential to the ROS species produced by
this enzyme [61]. A single site mutation, at His-222 (H222Q), was
shown to cause a shift in ROS production, converting the NOX4 enzyme
into a superoxide producer. Further mutational analysis of this loop
region, through single site mutations of two cysteine residues, provided
corroborating results, establishing control of H2O2 production at this
loop region.
To explore the possibility that our NOX4 E-loop directed antibody
might inﬂuence ROS production, both Amplex Red and L-012 assays
were performed to monitor the type and amount of ROS species
produced by a NOX4 overexpression system in the presence of 47-6
mAb (Fig. 1E-F, Supplementary Fig. 8). Constitutive hydrogen peroxide
production observed with the NOX4 overexpressing system is unper-
turbed by control rabbit IgG treatment, and attenuated by treatment
with the ﬂavin dehydrogenase inhibitor diphenylene iodonium (DPI)
(Fig. 1E). In comparison, no signiﬁcant decrease in hydrogen peroxide
production was observed following exposure to a range of antibody
concentrations, suggesting that while antibody 47-6 binds to the E-loop
region, this binding has little to no eﬀect on ROS production. Further
support for this observation was established by chemiluminescent L-
012 assay; superoxide production was not notably stimulated by 47-6
mAb treatment; therefore, exposure to the 47-6 mAb does not mimic
the eﬀect of a single-site mutation within the E-loop region (Fig. 1F).
The site of binding may be crucial, as the known His-222 mutation
which results in superoxide production is ~20 amino acids from the site
of 47-6 Ab binding (Fig. 1A-C). The stability of the antibody binding or
epitope position also may not be as eﬀective as direct mutation, or may
suggest that this region does not confer signiﬁcant structural support to
the E-loop such that perturbation would result in ROS modiﬁcation.
3.5. TGF-β1-mediated up-regulation of NOX4 in lung ﬁbroblasts
Transforming growth factor beta1 (TGF-β1) belongs to a family of
structurally related, secreted polypeptide cytokines that control cellular
growth, proliferation, diﬀerentiation, and apoptosis [69]. Stimulation
of smooth muscle cells [25,70], hepatocytes [36,71], and ﬁbroblasts
[34,37,72] with low concentrations of TGF-β1 has been shown to
signiﬁcantly increase NOX4 expression and ROS production. A myriad
of eﬀects have been related to the resultant NOX4 up-regulation,
varying by cell type. In studies of fetal rat and human hepatocytes,
treatment with TGF-β1 results in oxidative-stress mediated apoptosis
[73,74]. Regulated at the transcriptional level, NOX4 was established in
this system as the only signiﬁcantly up-regulated NOX isoform con-
tributing directly to caspase 3 activation and Rac-independent apopto-
sis [71]. Human pulmonary artery smooth muscle cells have also
demonstrated a TGF-β1 response, with increased NOX4 expression
and ROS production facilitating proliferation through the traditional
SMAD 2/3 pathway, independent of MAP kinase signaling [25]. In
contrast, diﬀerentiation is supported by TGF-β1-stimulated, nuclear-
localized NOX4 up-regulation, increased ROS production, and p38
phosphorylation in both murine embryo ﬁbroblasts (NIH3T3) and
human lung ﬁbroblasts (CCL-210) [34].
To support the investigative precedent for TGF-β1 mediated up-
regulation, we chose the human lung ﬁbroblasts (CCL-210) for stimula-
tion and Western analysis. After 24 h of starvation, ﬁbroblasts were
treated for ﬁxed times with 2 ng/mL TGF-β1, and subsequently
harvested for both RNA and protein expression evaluation (Fig. 1G).
Signiﬁcant up-regulation of NOX4 was noted, as early as 6 h, with
maximal expression at 24–48 h. Consistent with the gene expression
levels of NOX4, our monoclonal antibody detected increasing levels of
NOX4 protein upon TGF-β1 treatment, with increasing treatment time
resulting in higher NOX4 expression between 6 h and 24 h treatments.
3.6. NOX4 immunoreactivity is higher in human tumors than in normal
tissue
Having established the ability of our monoclonal antibody to detect
low levels of NOX4 in an endogenous system, we focused our studies on
an immunohistochemical examination of NOX4 expression in human
Fig. 1. Comprehensive characterization of NOX4 monoclonal antibody 47-6. (A) Multiple sequence alignment performed using Clustal Omega of the E-loop region residues for the NOX1-
4 enzymes. NOX5 and DUOX1/2 have short E-loop regions (< 10 amino acids) and therefore were not amenable to sequence alignment. (B) Western analysis carried out with samples
positive for NOX1 (64.9 kDa, HEK293 NOX1, NOXA1/NOXO1 stable cell line), NOX2 (~100 kDa, glycosylated form, RPMI 8226 human myeloma cell line), NOX4 (69.7 kDa, HEK293
MycDDK-NOX4 stable cell line WT1), NOX5 (83.1 kDa, KARPAS 299 HA-NOX5 stable cell line), and DUOX2 (Dx2) (175.4 kDa, HEK293 DUOX2/DUOXA2 stable cell line) expression.
Twenty micrograms per lane of total protein were loaded. Antibodies used to detect the various NADPH homologues are listed, with details in the Methods section. (C) Schematic
illustration of the NOX4 E-loop; the validated recognition sequence is highlighted (red). (D) Confocal microscopy of HEK293 parental, vector control, and MycDDK-NOX4 stable clones 1
(WT1) and 2 (WT2) under permeabilized and non-permeabilized conditions. Cells were incubated with 2 μg/mL 47-6 NOX4 mAb or rabbit IgG (control) prior to secondary antibody
staining with Alexa Fluor 488 (Green) and PI nuclei staining (red). (E) H2O2 production by HEK293 NOX4 stable clone 1 versus stable vector control cells measured with the Amplex Red
assay. NOX4 overexpressing stable cells were pre-incubated for 30 min at 37 °C with 47-6 mAb, rabbit IgG or DPI before addition to Amplex reagent solution. The assay was monitored
every 10 min for 90 min. (F) L-012 Assay measured superoxide generation across superoxide producing stable mutant H222Q NOX4 and WT NOX4 overexpressing stable cells treated
with 47-6 mAb or rabbit IgG. SOD (4U) treatment was used to verify superoxide production over 30 min, data was collected every 1.5 min for 30 min. (G) TGF-β1-stimulated NOX4 up-
regulation in lung ﬁbroblast cells veriﬁed by RNA quantiﬁcation and immunoblot analysis. Top: Quantitative real-time RT-PCR assay of relative NOX4 expression from 24 h starved lung
ﬁbroblasts (CCL-210) treated with vehicle control (Veh) or TGF-β1 (TGF) for 6 h, 24 h, or 48 h, normalized to β-Actin. This data represents the mean and standard deviation from
triplicate samples. Bottom: Western analysis of whole cell lysates from lung ﬁbroblasts treated with TGF-β1; 80 μg total protein loaded per lane. TGF-β1 treatment was veriﬁed by the
detection of phosphorylated SMAD2. ***, p<0.001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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cancers. NOX4 expression levels, relative to uninvolved normal tissues,
were assessed in a comprehensive library of formalin-ﬁxed, paraﬃn-
embedded tissue samples; 549 specimens of various malignancies and
matched normal tissues, inﬂammatory and benign lesions, including
samples of brain, bladder, breast, colon, esophagus, head and neck,
kidney, liver, lung, lymph node, ovary, pancreas, prostate, skin, soft
tissue, stomach, testis, thyroid, uterine cervix, and uterus were eval-
uated and scored for NOX4 expression (Supplementary Table 2).
Staining intensity was assessed by a pathologist (HM) using the
following scoring system: 0 (negative/no or blush staining), 1+ (weak),
2+ (moderate), and 3+ (strong) (Fig. 2A). The percentage of stained
tumor/lesional cells was estimated for each case where, 0= 0%−10%
were considered negative, 1 = 10–24%, 2=25–49%, 3≥50-of positive
cells. Cases with moderate to strong cytoplasmic reactivity of the
antibody on ≥10% of cells were considered to be high expressors.
Diﬀerential NOX4 staining was observed in bladder, esophagus,
head and neck, ovary, and prostate cancers and melanoma compared to
corresponding normal tissues (Table 1, Figs. 2–3, Supplementary
Fig. 9). NOX4 positive expression was detected in 19/19 transitional
cell carcinomas of the bladder; more than 50% of the samples were high
positive, compared to the corresponding normal bladder epithelial
tissue where the majority were low positive (87%). Similarly, esopha-
geal carcinoma samples showed a diﬀerential expression of NOX4
antigen relative to its corresponding non-neoplastic esophageal mucosa
(> 75% of the adenocarcinoma and>50% of the squamous carcinoma
cases were high positive). All the head and neck squamous cell
carcinomas, regardless of their origin, expressed NOX4; most (approxi-
mately 80%) were high positive. Supplementary Fig. 9A showed
reactivity of NOX4 antibody with squamous cell carcinoma. Normal
epithelia of the tongue (lower image) was negative with the NOX4 mAb
except the basal layer. Neither the normal prostate tissue nor the
samples of benign prostate hyperplasia were high positive, in contrast
to over 50% of the adenocarcinoma cases (Supplementary Fig. 9B).
Of signiﬁcance, the antibody to NOX4 reacted with almost all
melanomas (14/15, 93%) and none of the normal skin samples (n=8)
or the compound nevi (0/2) (Fig. 2B). Fifty percent of melanomas were
high positive for NOX4 (7 of 14 melanomas). Most melanomas showed
diﬀuse cytoplasmic positivity with a detectable membrane distribution
in half of the cases; nuclear and perinuclear distribution was observed
in 1/3 of the samples (Fig. 4A). By subtype, serous ovarian carcinomas
demonstrated NOX4 overexpression in 8/8 tissues (100%) and muci-
nous ovarian tissue displayed moderate to strong NOX4 staining for 7/9
(78%), samples, relative to the corresponding normal ovarian tissues 3/
8. Most of the high positive samples were histologically categorized as
moderately- to well-diﬀerentiated. Fig. 4B, shows a sample from a
moderately diﬀerentiated serous ovarian adenocarcinoma that demon-
strated perinuclear localization of NOX4.
NOX4 was also detected in a signiﬁcant proportion of small cell lung
carcinomas (11/12, 92%), gastric carcinomas (12/17, 71%) and breast
carcinomas (18/20, 90%). Uterine (cervix) squamous cell carcinomas
had the lowest expression of positive tumors (56%). This is the ﬁrst
broad, systematic immunohistochemical analysis of NOX4 expression in
human malignancies. Previous studies have examined small subsets of
cancers, including bladder [17], breast and ovarian [75], and liver
tumors [18]. We have identiﬁed several malignant histologies (esopha-
geal, head and neck, and prostate carcinomas) that have not previously
been reported to show substantial NOX4 expression by IHC. Further
investigation is necessary to determine the relevance of NOX4 activity
in these unexplored systems.
3.7. Investigation of NOX4 in ovarian cancer cell lines
The accumulation of reactive oxygen species during the progression
of ovarian cancer [76–81], and its eﬀects on increased MKP3 degrada-
Fig. 2. Immunohistochemical (IHC) staining of melanoma tissues demonstrating NOX4 expression. (A) Depiction of melanoma tissues across scoring intensities from weak (1+),
moderate (2+), and strong (3+). (B) Tissues stained with NOX4 mAb (47-6), haemotoxylin and eosin (H & E), or normal rabbit isotype control (IgG2) across normal and malignant skin
samples. All samples are digitally magniﬁed at 10x.
J.L. Meitzler et al. Redox Biology 13 (2017) 182–195
189
tion and subsequent ERK 1/2 activation [82] or the promotion of tumor
angiogenesis [83] have been documented, but few studies have
investigated NOX4 as a hydrogen peroxide source contributing to the
development or progression of ovarian malignancies [22,84].
Supported by the results of the tissue microarray analysis and
previous observations of NOX4 expression in cell lines proﬁled by the
genomic database from the cancer cell line encyclopedia (CCLE) [4],
several ovarian cancer cell lines were examined for levels of NOX4 and
p22phox, the necessary components for enzymatic hydrogen peroxide
production. COV362, OVCAR3, and SKOV3 cell lines were evaluated by
quantitative PCR to determine the expression level of each gene
(Fig. 5A). Signiﬁcant levels of NOX4 were found in COV362, seven
times greater than in OVCAR3 cells. Western analysis of total mem-
brane preparations of these cell lines with the mAb 47-6 demonstrated
this disparity at the protein level (Fig. 5B). To conﬁrm that our antibody
successfully recognized the NOX4 protein, we employed short interfer-
ing RNA (pooled NOX4 siRNA and speciﬁc siRNA #07) to knockdown
endogenous NOX4 in COV362 cells (Fig. 5C). As expected, the NOX4
knockdown achieved was veriﬁed both at the RNA and protein level,
leaving the level of p22phox unperturbed.
Having veriﬁed the presence of NOX4 protein in the COV362 cell
line, we utilized confocal microscopy to deﬁne cellular localization.
COV362 and SKOV3 cells, chosen to aﬀord the broadest diﬀerence in
NOX4 expression levels, were evaluated both under permeabilized and
unpermeabilized conditions (Fig. 5D). No signiﬁcant staining was noted
at the cellular surface of non-permeable cells, suggesting little to no
expression of NOX4 at the plasma membrane. Interestingly, COV362
cells demonstrated perinuclear staining in the membrane-permeable
system, deﬁned by NOX4-related green ﬂuorescence hugging the DAPI
stained nuclei while remaining easily distinguishable from cytoskeletal
staining (rhodamine phalloidin). Similar staining is absent in the
SKOV3 cells, further supporting the identity of NOX4. Localization
within multiple intracellular structures cannot be ruled out, as regions
of focused, increased staining were noted in the perinuclear region,
reminiscent of the endoplasmic reticulum (ER) or Golgi apparatus.
Recent studies support NOX4 intracellular localization (nucleus, nucle-
ar envelope, mitochondria, ER), as opposed to plasma membrane
association, when observed in endogenous systems [30,49,51,52].
4. Discussion
Eﬀorts continue to clarify the role of hydrogen peroxide in
intracellular signaling cascades responsible for induction and main-
tenance of an oncogenic phenotype in cancer cells [85,86]. NOX4 is
among many ROS producing enzymes under study as potential sources
of ROS producing oxidative DNA damage [87,88]. Unfortunately, high
quality, commercial monoclonal antibodies against NOX4 have not
been available to aid these studies [60]. The few available academic
antibody sources, while reliable, were not designed for extracellular
binding and/or because they are polyclonal probes, suﬀer from
prominent non-speciﬁc binding and variation in quality from multiple
animal hosts. To address this need, we developed a novel NOX4
monoclonal antibody whose antigen resides in the extracellular E-loop
region of the enzyme and that has been validated for immunohisto-
chemical studies.
Our NOX4 antibody (47-6) was raised in a rabbit host, with a dual
antigen inoculation strategy using peptide and ﬁxed overexpressing
NOX4 cells. This new tool was validated for isoform speciﬁcity
(Fig. 1B), through detection of overexpressing protein without display-
ing signiﬁcant non-speciﬁc bands. Further characterization, by Western
analysis of truncated E-loop constructs was undertaken, deﬁning a 21
amino acid region recognized by the 47-6 antibody (Fig. 1C,
Supplementary Fig. 3). This sequence displays a lack of ﬁdelity with
both mouse and rat NOX4 isoforms, unlike the remainder of the protein
where high sequence conservation is observed (Supplementary Fig. 4A).
Comparison of overexpressed NOX4 constructs conﬁrmed the inability
of our monoclonal antibody to bind to mouse NOX4 protein
(Supplementary Fig. 4B). The incapability of our 47-6 antibody to
detect mouse or rat NOX4 may prove opportune in the context of
implanted human tumor studies, providing the ability to isolate NOX4
enzymatic changes from host contamination. To move beyond over-
expression systems, TGF-β1 mediated up-regulation of NOX4 was
employed to demonstrate antibody sensitivity. TGF-β1 has been
identiﬁed as a stimulant of NOX4 expression in several cell systems,
including smooth muscle cells, hepatocytes, and ﬁbroblasts; CCL-210
lung ﬁbroblasts treated with 2 ng/mL TGF-β1 up-regulated NOX4 as
shown by qPCR and detected through Western analysis with 47-6
(Fig. 1G).
Table 1
Distribution of expression levels of NOX4 in human malignancies. Tissues that were scored [+] as weak (1+) for NOX4 staining were considered low expressors, and those that stained
moderate (2+) to strong (3+) high expressors; unstained/unscored tissues are related as [-]. Represented within parentheses are the relative percentages of tissues. See Supplementary
Table 2 for speciﬁc details on scoring.
Organ Pathologic diagnosis No. [+]/Total (%) No.[-]/Total (%) Low Expressors [No. (%)] High Expressors [No. (%)]
Bladder Transitional cell carcinoma 19/19 (100) 0 (0) 9 (47) 10 (53)
Normal bladder Tissue 8/8 (100)a 0 (0) 7 (87) 1 (13)
Esophagus Adenocarcinoma 9/9 (100) 0 (0) 2 (22) 7 (78)
Squamous cell carcinoma 9/9 (100) 0 (0) 4 (44) 5 (56)
Normal esophagus tissue 6/6 (100)b 0 (0) 4 (67) 2 (33)
Head and Neck Squamous cell carcinoma 19/19 (100) 0 (0) 4 (21) 15 (79)
Normal tongue tissue 6/6 (100)c 0 (0) 2 (33) 4 (67)
Ovary Serous adenocarcinoma 8/8 (100) 0 (0) 6 (75) 2 (25)
Mucinous adenocarcinoma 7/9 (78) 2/9 (22) 3 (43) 4 (57)
Normal ovary tissue 3/8 (38) 5/8 (62) 3 (100) 0 (0)
Skin Squamous cell carcinoma 12/14 (86) 2/14 (14) 10 (83) 2 (17)
Malignant melanoma 14/15 (93) 1/15 (7) 7 (50) 7 (50)
Intradermal nevus 2/4 (50) 2/4 (50) 1 (50) 1 (50)
Normal skin tissue 0/8(0) 8/8 (100) 0 (0) 0 (0)
Prostate Adenocarcinoma 12/19 (63) 7/19 (37) 5 (42) 7 (58)
Hyperplasia of prostate 1/2 (50) 1/2 (50) 1 (100) 0 (0)
Normal Prostate 4/6 (67) 2/6 (33) 4 (100) 0 (0)
a Only 5/8 samples have epithelium.
b 3/6 have squamous epithelium.
c 5/6 have squamous epithelium.
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Therapeutic interventions focusing on ROS formation can involve
strategies to either increase or decrease oxidative stress [2]. Increased
ROS scavenging, by enhanced expression of antioxidants (SOD, cata-
lase) or decreased pro-oxidant enzyme expression, may decrease
oxidative tone and depress tumor growth and migration [89–91].
Alternatively, disrupting oxidant removal, causing an accumulation of
excess ROS in malignant cells, could initiate a beneﬁcial apoptotic
cascade [92]. NOX4 oxidant production appears to be related to the
structural integrity of the E-loop region [61]. Our E-loop recognizing
monoclonal antibody was therefore tested for eﬀects on both hydrogen
peroxide and superoxide production (Fig. 1E-F, Supplementary Fig. 8).
Amplex Red and L-012 substrates were utilized as probes for hydrogen
Fig. 3. Representative examples of NOX4 immunostaining from a broad array of malignant versus normal tissues. IHC staining of BioMax Multiple Organ TMA MC6163 for NOX4
expression was scored utilizing the following system: 0 = negative/no or blush staining, 1+= weak, 2+=moderate, and 3+= strong. The percentage of bladder (A), esophageal (B),
and ovarian (C) tissues stained with NOX4 is illustrated graphically (left), with tissue images depicting the staining pattern of NOX4 mAb (47-6), haemotoxylin and eosin (H & E), or
normal rabbit isotype control (IgG2) (right). Malignant tissue staining demonstrated a signiﬁcant NOX4 expression increase relative to the corresponding normal tissues.
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peroxide and superoxide production, respectively. Neither assay,
monitored for up to 90 min, revealed a signiﬁcant eﬀect on ROS
production when NOX4 overexpressing HEK293 cells were incubated
with the 47-6 antibody. Although it is unfortunate that our antibody
does not appear to hold therapeutic value as a direct enzymatic eﬀector,
the importance of the E-loop region toward enzymatic function should
continue to be explored.
Application of our antibody to a human tumor tissue microarrays
has provided novel insights into the expression of NOX4 in human
tumors (Figs. 2 and 3, Table 1, Supplementary Table 2). High levels of
NOX4 expression were found in previously-characterized tissues,
including kidney, brain, and pancreas; however, signiﬁcant diﬀerential
expression, deﬁned by greater expression in malignant tissues versus
normal, was noted only in bladder, esophageal, head and neck, ovarian
and prostate carcinomas and malignant melanoma. No major studies, to
date, have focused primarily on NOX4 in esophageal adenocarcinoma
or squamous cell carcinoma. This observation may provide additional
relevance to a recent study suggesting that TGF-β−related oxidative
stress promoted pre-malignant basal cell hyperplasia in the esophagus
which was associated with a 2.5-fold increase in NOX4 mRNA [93]. Our
IHC data have identiﬁed esophageal carcinoma as a potential focus for
future NOX4 research, joining ongoing but preliminary eﬀorts in
bladder, head and neck, and ovarian cancers, and malignant melanoma.
Ovarian cancer has the highest morality rate of all gynecological
cancers and is the ﬁfth leading cause of cancer-related death in women
[94,95]; and oxidative stress has been linked to the pathogenesis of
ovarian cancer [76,79,81,96]. It is possible that NOX4 may play an
underappreciated role in ovarian cancer, an hypothesis supported both
by observations of increased NOX4 expression in malignant ovarian
tissues and through cell line proﬁling (Figs. 3 and 5) [7]. Our
monoclonal antibody conﬁrmed that COV362 ovarian cancer cells
clearly demonstrate expression of NOX4 enzyme; expression of its
necessary activity partner p22phox was also validated. NOX4 expression,
through confocal microscopy, was speciﬁcally shown to be localized to
the nuclear region, without signiﬁcant plasma membrane association
(Fig. 5D). Unchecked intracellular hydrogen peroxide generation from
NOX4 could foster DNA damage and promote aberrant cellular signal-
ing; further investigative eﬀorts are required to establish the role of
NOX4 in this disease. The lack of plasma membrane localized NOX4,
furthermore, suggests that eﬀorts to evaluate ROS generation in tumor
biology should focus on tools that measure intracellular ROS, including
ﬂuorescent dyes, and DNA damage markers (i.e. anti 8-oxoguanine
antibodies). By relying on assay strategies that measure extracellular
hydrogen peroxide production, studies may be missing crucial informa-
tion regarding the eﬀects of NOX4-dependent ROS generation.
In summary, we have developed a novel immunologic tool for study
of the NOX4 enzyme. Our monoclonal antibody (47-6) has proven to be
isoform selective and sensitive for investigative eﬀorts that involve
endogenous expression levels, and therefore is an important resource to
support future NOX4 studies. Insights into the role of NOX4 in tumor
biology, provided by IHC, demonstrate marked overexpression of NOX4
in several malignancies, several for the ﬁrst time. Our future studies
will focus on understanding the speciﬁc role of H2O2 in oxidative
signaling and DNA oxidation for tumors that have been shown to
overexpress NOX4.
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